Asia Pacific in-vitro Diagnostics Market is projected to reach US$ 23.01 billion by 2031, up from US$ 15.5 billion by 2022, growing at a CAGR of 4.67% from 2023-2031.
The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, coupled with the growing demand for early and accurate diagnosis, are some of the key factors driving the growth of the Asia Pacific IVD market. The rise in healthcare expenditure, along with the increasing adoption of point-of-care (POC) testing, is also contributing to the growth of the market.
China, Japan, and India are among the major in-vitro diagnostics market driving the growth of the Asia Pacific market. These countries have a large population base and are witnessing a significant increase in the incidence of chronic diseases, creating a huge demand for diagnostic tests. Furthermore, the COVID-19 pandemic has also contributed to the growth of the market in the Asia Pacific region. The outbreak has led to a surge in demand for COVID-19 diagnostic tests, including RT-PCR tests, antigen tests, and antibody tests, which has further boosted the growth.
The Asia Pacific IVD market is highly competitive, with several established players, including Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Sysmex Corporation, among others, dominating the market. These companies are focusing on expanding their product portfolio and developing innovative diagnostic technologies to strengthen their market position.
To Get more Insights, Request A Free Sample
The Asia Pacific region is witnessing a significant increase in the prevalence of chronic diseases, which is driving the growth of the IVD market in the region. According to the World Health Organization, chronic diseases account for 71% of all deaths in the Asia Pacific region. Factors such as an aging population, unhealthy lifestyles, and environmental factors are contributing to the rise in chronic diseases. This has created a high demand for early and accurate diagnosis, which is driving the growth in the Asia Pacific region.
The Asia Pacific region is experiencing a rise in healthcare expenditure, which is contributing to the growth of the IVD market. With the rising demand for healthcare services, governments and private players are investing heavily in healthcare infrastructure, including diagnostic facilities. The increasing healthcare expenditure is enabling the development of advanced diagnostic technologies and the expansion of the market. Diagnostic tests are a critical part of healthcare services, and the growth of the market is closely tied to the growth of the healthcare industry in the region.
The Asia Pacific IVD market faces a significant regulatory burden, which can hinder its growth. The regulatory process for the approval of diagnostic tests is complex, time-consuming, and expensive. This can deter manufacturers from introducing new products in the market. Additionally, different countries in the region have different regulatory requirements, which can further complicate the regulatory process. The high cost and lengthy approval process can limit innovation, and delay the adoption of new technologies.
By product & services, the Asia Pacific IVD market is expected to be dominated by reagents, which are estimated to account for more than 75% of the market share. Reagents are essential components in diagnostic tests, and the increasing demand for accurate and reliable diagnostic tests is driving the growth of the reagents market in the region. The Asia Pacific market is also driven by the increasing adoption of advanced diagnostic technologies, such as molecular diagnostics and point-of-care testing.
By technique, the immunodiagnostics segment is expected to dominate the Asia Pacific in-vitro diagnostics market with a market share of 29%. Immunodiagnostics is a technique that uses antibodies to detect antigens in patient samples. The increasing prevalence of chronic diseases and infectious diseases, coupled with the rising demand for early and accurate diagnosis, is driving the growth of the immunodiagnostics market in the Asia Pacific region.
By application, the infectious disease diagnostics segment is expected to dominate the Asia Pacific in-vitro diagnostics market with a market share of over 49%. The increasing incidence of infectious diseases, such as COVID-19, hepatitis, and tuberculosis, is driving the growth of the infectious disease diagnostics market in the region. Additionally, the growing awareness about the importance of early and accurate diagnosis of infectious diseases is contributing to the growth of the infectious disease diagnostics market in the region.
By end-users, the hospital segment is expected to dominate the Asia Pacific in-vitro diagnostics market with a market share of 40%. Hospitals are the primary healthcare providers in the region, and the increasing demand for healthcare services is driving the growth of the hospital segment. Additionally, the growing adoption of advanced diagnostic technologies and the increasing need for accurate and reliable diagnosis is contributing to the growth of the hospital segment in the Asia Pacific IVD market.
To Understand More About this Research: Request A Free Sample
Japan holds a significant position in the Asia Pacific in-vitro diagnostics (IVD) market, accounting for more than 28% of the market share. The Japanese IVD market is well established, with a strong regulatory framework, advanced healthcare infrastructure, and a high level of healthcare spending. The Japanese government has been actively promoting the development and adoption of innovative IVD technologies, which has further accelerated the growth of the market.
The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and diabetes is a significant driver of the Japanese IVD market. The rising incidence of these diseases has created a high demand for early and accurate diagnosis, which has further propelled the growth in Japan. Additionally, the aging population in Japan has contributed to the growth of the market, as the demand for healthcare services, including diagnostic tests, continues to increase.
The adoption of point-of-care (POC) testing is another significant driver of the Japanese in-vitro diagnostics market. POC testing provides quick and accurate results and is particularly beneficial in emergency and critical care situations. The growing demand for POC testing has further boosted the growth.
The Japanese market is dominated by established players such as Roche Diagnostics, Sysmex Corporation, Abbott Laboratories, and Siemens Healthineers. These companies are actively engaged in developing advanced IVD technologies, expanding their product portfolio, and investing in research and development to maintain their market position.
Despite the significant growth potential of the Japanese IVD market, it faces challenges such as a complex and time-consuming regulatory process and increasing competition from emerging markets such as China and India. The high regulatory burden can slow down the approval and adoption of new products, limiting innovation in the market.
By Product & Services
By Technique
By Application
By End-User
By Country
LOOKING FOR COMPREHENSIVE MARKET KNOWLEDGE? ENGAGE OUR EXPERT SPECIALISTS.
SPEAK TO AN ANALYST
.png)
Features | Type of License | |||
 Single User |   Multi User |  Corporate | ||
| e-Access | ✓ | ✓ | ✓ | |
User Sharing | 1 User Only | 2-6 Users | Unlimited within Company/Enterprise | |
⨉ | ⨉ | ✓ | ||
Free Customization | Up To 30 hrs work | Up To 60 hrs work | Up To 80 hrs work | |
Deliverable |
| ✓ | ✓ | ✓ |
| ⨉ | ✓ | ✓ | |
| ⨉ | ⨉ | ✓ | |
Analyst Support | 4 Month Post purchase | 7 Month Post purchase | One Year Post purchase | |
Free Report update in next update cycle | ⨉ | ⨉ | ✓ | |
Free Industry Update (Within 180 days) | ⨉ | ⨉ | ✓ | |
Benefit | Up to 20% off on next purchase | Up to 30% off on next purchase | Up to 40% off on next purchase | |
| Report ID: AA0423410 | Delivery: 2 to 4 Hours 
.svg)
